Identifying and reducing disparities in successful addiction treatment completion: testing the role of Medicaid payment acceptance

Table 3 Multilevel Oaxaca–blinder decomposition of differences for Mexican Americans and non-latino whites in treatment completion

	b	SE	95% CI	p
Overall
Mexican American	0.175	0.022	0.132, 0.218	< .001
White	0.144	0.026	0.093, 0.196	< .001
Difference	0.031	0.021	−0.012, 0.073	.154
Explained	0.069	0.019	0.031, 0.106	< .001
Unexplained	−0.038	0.014	−0.066, −0.010	.009
Program variables
Wave 2^a	−0.002	0.002	−0.006, 0.003	.492
Medicaid payment	0.013	0.005	0.003, 0.023	.009
Licensed	0.000	0.001	−0.001, 0.002	.669
Accredited^b	−0.001	0.006	−0.012, 0.010	.857
Cross-level interaction
Wave × Mexican American	0.008	0.007	−0.005, 0.021	.230
Medicaid × Mexican American	0.015	0.008	−0.001, 0.032	.065
Client variables
Female	0.000	0.000	0.000, 0.001	.458
Age	−0.003	0.002	−0.006, 0.001	.147
Education level	0.000	0.002	−0.005, 0.004	.843
Primary drug^c
Alcohol	−0.005	0.001	−0.008, −0.002	< .001
Methamphetamine	0.009	0.003	0.004, 0.015	.001
Marijuana or hashish	0.005	0.002	0.002, 0.008	.003
Other	−0.003	0.001	−0.005, −0.002	< .001
Days used^d	0.025	0.010	0.006, 0.044	.012
Age at first use	0.000	0.001	−0.001, 0.002	.714
Medicaid eligibility	−0.001	0.002	−0.004, 0.002	.345
Mental health disorder	0.005	0.002	0.002, 0.009	.006
Treatment type^e
Methadone	−0.003	0.003	−0.009, 0.003	.296
Residential	0.005	0.004	−0.002, 0.013	.154

^aWave 1 (2011) used as reference
^bAccreditation by the Joint Commission
^cHeroin used as reference
^dDuring 30 days prior to admission
^eOutpatient used as reference
The 1.1% disparity is explained by differences in programs accepting Medicaid payments, professional accreditation, client Medicaid eligibility and treatment type, and differences unexplained by model covariates

ISSN: 1747-597X